Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating Expenses:
Research and development	$ 4,747,557	$ 8,203,926
General and administrative	3,306,668	5,115,978
Total Operating Expenses	(8,054,225)	(13,319,904)
Other Income/Expense:
Gain on settlement of lawsuit	825,000	172,376
Research and development tax credit	26,325
Investment and interest income	19,560	31,304
Interest expense	(969,715)	(401,592)
Net Loss	(8,153,055)	(13,517,816)
Dividend paid-in kind to preferred shareholders		(14,107)
Net Loss Applicable to Common Shareholders	$ (8,153,055)	$ (13,531,923)
Basic and Diluted Loss Per Common Share	$ (0.02)	$ (0.04)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	382,338,471	369,231,518